Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618449 · ClinicalTrials.gov registry record · Phase 4
Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
A Phase 4 study of Trachoma and Chlamydia Trachomatis, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,139
- Enrollment target
- 2
- Study locations
NCT00618449 is a Phase 4 study of Trachoma and Chlamydia Trachomatis that has completed, run by University of California, San Francisco. The registered enrollment target is 1,139 participants, below the 80,281-participant average among 4 other Trachoma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00618449, a Phase 4 study of Trachoma and Chlamydia Trachomatis, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,139 participants
- Enrollment target
- 2
- Study locations
Study Summary
Trachoma is a disease of poverty, which in the hyperendemic areas affects all individuals by the time they are two years old. Active disease is concentrated in children and occurs sporadically in adults. Infection is more widespread. It is anticipated that 25% of the children will be blinded by this disease if they live to be 60 years of age. The blindness rates are higher in women, presumably because of their closer contact with children who can infect them and add to damage from infections the women had while young. This proposal is to better define how azithromycin in community-based treatment can be used to eliminate blinding trachoma. We will also take the opportunity to join these field studies with genetic epidemiologic studies to better understand the dynamic epidemiology of Chlamydia trachomatis infection in a trachoma endemic area. The empiric data generated from the treatment/follow-up studies, together with the information on sources and spread patterns from genetic epidemiology will be used to generate more robust models to guide future treatment/re-treatment protocols. We propose to conduct a randomized, community based trial in the Maradi region of Niger to test the hypothesis that two community wide azithromycin treatments, spaced one month apart, are significantly more effective in reducing ocular C. trachomatis infection and trachoma at one year compared to a single mass azithromycin treatment.
Conditions Studied
Interventions
- DRUG Azithromycin
- DRUG Azithromcyin
Study Locations (2)
California
- Chlamydia Research Laboratory - San Francisco
Other
- Programme National de Lutte Contre la Cécité - Niamey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,139 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618449
The ClinicalTrials.gov registry entry for NCT00618449 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,139 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 80,281-participant average among 4 other Trachoma trials with a reported enrollment target (99% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Trachoma appearing as the primary indexed condition, and to 2 interventions - of which Azithromycin is the first listed.
NCT00618449 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Other.
Frequently Asked Questions
What is clinical trial NCT00618449 about?
NCT00618449 is a clinical study titled "Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger". Trachoma is a disease of poverty, which in the hyperendemic areas affects all individuals by the time they are two years old. Active disease is concentrated in children and occurs sporadically in adults. Infection is more widespread. It is anticipated that 25% of the children will be blinded by this...
What is the current status of trial NCT00618449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,139 participants. The study started on 2008-01. Estimated completion is 2009-08.
What conditions does trial NCT00618449 study?
This clinical trial studies the following conditions: Trachoma, Chlamydia Trachomatis.
What interventions are being tested in trial NCT00618449?
The interventions under investigation include: Azithromycin (DRUG), Azithromcyin (DRUG).
Who is sponsoring clinical trial NCT00618449?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00618449 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trachoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Kebele Elimination of Trachoma for Ocular Health
ACTIVE NOT RECRUITING · Phase 4
-
Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania
COMPLETED · Phase 4
-
Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger
COMPLETED · Phase 4
-
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.